Nestl is the best known for its kit kat chocolate pubs and nespresso coffee. but current m&a techniques by the swiss meals and drink monster are rendering it look progressively like a drug organization.

Its most recent purchase, california-based aimmune therapeutics, marks the companys biggest gamble however on wellness technology. nestl features decided to pay $34.50 a share to achieve full ownership of this us biotech group, which made headlines early in the day in 2010 with regards to won united states approval for peanut allergy therapy palforzia. the offer presents a 173 per cent advanced to aimmunes closing price on friday, and values the business at $2.6bn, including financial obligation.

The deal takes nestl supervisor ulf mark schneider back in familiar territory. he led german health care business fresenius for 13 years before joining nestl in 2017. their passions tend to be shown in discounts. since he took over nestl, it's offered off underperforming assets such as for instance lunch animal meat and bulked up in fast-growing places particularly meat replacements and medical nutrition.

The blend of meals and medicines isn't as strange because sounds. sales of ready-made foods take the wane. food and pharmaceutical groups tend to be converging around high-margin, non-prescription health products, for both people and creatures. nestl, including, tends to make puppy food that claims to fight dementia.

Having dedicated to products that cover anything from intestinal medicine to supplements, nestl is currently concentrating on the foodstuff allergy market. around 240m folks global suffer from food allergies, in line with the world allergy company. peanut allergies will be the most frequent. nestl reckons aimmunes palforzia therapy, which can be made from peanut flour and offered as a powder blended with foods, could deliver possible annual product sales of $1bn later on this decade.

The keyword is possible. like many biotech businesses, aimmune has actually confirmed made no sales and reported a loss of $248m this past year. it will take time when it comes to investment to settle. however with market valuation of more than sfr303bn ($336bn) and many cash from recent disposals, nestl are able is patient.

Lex suggests the fts due diligence newsletter, a curated briefing in the realm of mergers and acquisitions. clickhereto register.